Innoviva, Inc. (INVA)
USD 18.72
(0.38%)
USD 18.72
(0.38%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 248.96 Million USD | -30.61% |
| 2022 | 322.25 Million USD | -42.25% |
| 2021 | 478.17 Million USD | 15.83% |
| 2020 | 386.41 Million USD | 28.12% |
| 2019 | 265.42 Million USD | 4.85% |
| 2018 | 248.08 Million USD | 29.0% |
| 2017 | 191.85 Million USD | 66.13% |
| 2016 | 125.9 Million USD | 238.81% |
| 2015 | 46.97 Million USD | 235.07% |
| 2014 | -24.46 Million USD | 84.03% |
| 2013 | -26.08 Million USD | -2837.85% |
| 2012 | -21.89 Million USD | 94.88% |
| 2011 | -101.73 Million USD | -41.33% |
| 2010 | -71.48 Million USD | 2.1% |
| 2009 | -73.7 Million USD | 2.49% |
| 2008 | -81 Million USD | 54.16% |
| 2007 | -164.5 Million USD | 5.98% |
| 2006 | -179.17 Million USD | -20.3% |
| 2005 | -145.44 Million USD | -47.54% |
| 2004 | -97.01 Million USD | -46.58% |
| 2003 | -67.25 Million USD | 13.73% |
| 2002 | -77.95 Million USD | -44.98% |
| 2001 | -53.77 Million USD | 48.26% |
| 2000 | -103.92 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 64.6 Million USD | -138.67% |
| 2024 Q1 | 35.75 Million USD | 35.63% |
| 2023 Q1 | 51.53 Million USD | 78.84% |
| 2023 Q4 | 47.51 Million USD | 53.28% |
| 2023 Q3 | 31 Million USD | -19.71% |
| 2023 Q2 | 38.61 Million USD | -25.07% |
| 2023 FY | - USD | -30.61% |
| 2022 Q1 | 77.8 Million USD | -25.39% |
| 2022 Q4 | 28.81 Million USD | -4.29% |
| 2022 FY | - USD | -42.25% |
| 2022 Q3 | 30.1 Million USD | -65.13% |
| 2022 Q2 | 86.34 Million USD | 10.98% |
| 2021 FY | - USD | 15.83% |
| 2021 Q1 | 82.54 Million USD | -2.18% |
| 2021 Q3 | 97.81 Million USD | 2.3% |
| 2021 Q4 | 104.27 Million USD | 6.61% |
| 2021 Q2 | 95.6 Million USD | 15.83% |
| 2020 Q1 | 80.94 Million USD | 8.0% |
| 2020 FY | - USD | 28.12% |
| 2020 Q2 | 79.43 Million USD | -1.87% |
| 2020 Q3 | 87.91 Million USD | 10.68% |
| 2020 Q4 | 84.37 Million USD | -4.03% |
| 2019 Q4 | 74.95 Million USD | 14.22% |
| 2019 Q3 | 65.62 Million USD | 7.3% |
| 2019 Q2 | 61.15 Million USD | 7.89% |
| 2019 FY | - USD | 4.85% |
| 2019 Q1 | 56.68 Million USD | -27.07% |
| 2018 FY | - USD | 29.0% |
| 2018 Q4 | 77.72 Million USD | 32.02% |
| 2018 Q1 | 41.16 Million USD | -35.63% |
| 2018 Q2 | 66.56 Million USD | 61.71% |
| 2018 Q3 | 58.87 Million USD | -11.55% |
| 2017 Q2 | 51.65 Million USD | 52.55% |
| 2017 FY | - USD | 66.13% |
| 2017 Q4 | 63.94 Million USD | 75.12% |
| 2017 Q3 | 36.51 Million USD | -29.31% |
| 2017 Q1 | 33.86 Million USD | -11.98% |
| 2016 Q3 | 28.13 Million USD | 1.38% |
| 2016 Q4 | 38.47 Million USD | 36.73% |
| 2016 Q1 | 17.59 Million USD | 1.41% |
| 2016 Q2 | 27.75 Million USD | 57.76% |
| 2016 FY | - USD | 238.81% |
| 2015 Q4 | 17.34 Million USD | 104.6% |
| 2015 Q2 | 5.17 Million USD | 153.9% |
| 2015 Q1 | 2.03 Million USD | 2046.32% |
| 2015 Q3 | 8.47 Million USD | 63.78% |
| 2015 FY | - USD | 235.07% |
| 2014 FY | - USD | 84.03% |
| 2014 Q4 | 95 Thousand USD | 101.43% |
| 2014 Q3 | -6.66 Million USD | 1.36% |
| 2014 Q2 | -6.75 Million USD | 89.22% |
| 2014 Q1 | -62.65 Million USD | -37.04% |
| 2013 Q1 | -31.48 Million USD | -12.62% |
| 2013 Q4 | -45.72 Million USD | -5.62% |
| 2013 Q3 | -43.28 Million USD | -37.81% |
| 2013 Q2 | -31.41 Million USD | 0.24% |
| 2013 FY | - USD | -2837.85% |
| 2012 FY | - USD | 94.88% |
| 2012 Q1 | 86.04 Million USD | 357.76% |
| 2012 Q3 | -31.3 Million USD | 12.34% |
| 2012 Q4 | -27.96 Million USD | 10.68% |
| 2012 Q2 | -35.7 Million USD | -141.5% |
| 2011 Q2 | -21.78 Million USD | -11.66% |
| 2011 Q3 | -27.06 Million USD | -24.27% |
| 2011 Q4 | -33.38 Million USD | -23.31% |
| 2011 FY | - USD | -41.33% |
| 2011 Q1 | -19.5 Million USD | -19.72% |
| 2010 Q1 | -19.59 Million USD | -1.08% |
| 2010 Q4 | -16.29 Million USD | 10.89% |
| 2010 Q3 | -18.28 Million USD | -2.67% |
| 2010 FY | - USD | 2.1% |
| 2010 Q2 | -17.81 Million USD | 9.12% |
| 2009 FY | - USD | 2.49% |
| 2009 Q4 | -19.38 Million USD | 1.06% |
| 2009 Q2 | -19.96 Million USD | -36.99% |
| 2009 Q1 | -14.57 Million USD | -6.84% |
| 2009 Q3 | -19.59 Million USD | 1.87% |
| 2008 FY | - USD | 54.16% |
| 2008 Q1 | -28.46 Million USD | 11.92% |
| 2008 Q4 | -13.64 Million USD | 27.93% |
| 2008 Q3 | -18.93 Million USD | -31.78% |
| 2008 Q2 | -14.36 Million USD | 49.53% |
| 2007 Q3 | -33.92 Million USD | 27.64% |
| 2007 FY | - USD | 5.98% |
| 2007 Q2 | -46.88 Million USD | 8.76% |
| 2007 Q4 | -32.31 Million USD | 4.75% |
| 2007 Q1 | -51.38 Million USD | -28.1% |
| 2006 FY | - USD | -20.3% |
| 2006 Q4 | -40.11 Million USD | 0.71% |
| 2006 Q1 | -50.7 Million USD | -18.2% |
| 2006 Q2 | -43.75 Million USD | 13.71% |
| 2006 Q3 | -40.4 Million USD | 7.66% |
| 2005 Q1 | -31.99 Million USD | -20.28% |
| 2005 Q3 | -38.34 Million USD | -19.0% |
| 2005 FY | - USD | -47.54% |
| 2005 Q4 | -42.89 Million USD | -11.88% |
| 2005 Q2 | -32.22 Million USD | -0.72% |
| 2004 Q2 | -26.14 Million USD | 0.0% |
| 2004 Q3 | -22.12 Million USD | 15.38% |
| 2004 Q4 | -26.59 Million USD | -20.2% |
| 2004 FY | - USD | -46.58% |
| 2003 FY | - USD | 13.73% |
| 2002 FY | - USD | -44.98% |
| 2001 FY | - USD | 48.26% |
| 2000 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Absci Corporation | -95.45 Million USD | 360.809% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 231.535% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 196.406% |
| Alzamend Neuro, Inc. | -9.88 Million USD | 2618.078% |
| Apollomics, Inc. | -171.74 Million USD | 244.957% |
| 180 Life Sciences Corp. | -22.13 Million USD | 1224.784% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | 894.029% |
| Bicycle Therapeutics plc | -183.4 Million USD | 235.747% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | 432.768% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 250.501% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | 1255.857% |
| Chimerix, Inc. | -92.97 Million USD | 367.774% |
| CRISPR Therapeutics AG | -202.7 Million USD | 222.821% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | -956.124% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | 460.806% |
| Fortress Biotech, Inc. | -133.64 Million USD | 286.287% |
| Fortress Biotech, Inc. | -133.64 Million USD | 286.287% |
| Gritstone bio, Inc. | -126.86 Million USD | 296.243% |
| Allakos Inc. | -189.91 Million USD | 231.09% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | 613.563% |
| Cara Therapeutics, Inc. | -117.65 Million USD | 311.611% |
| Cytokinetics, Incorporated | -456.68 Million USD | 154.515% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | 362.694% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | 162660.644% |
| NLS Pharmaceutics AG | -11.79 Million USD | 2210.608% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | 297.829% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | 1932285.684% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | 343.444% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | 381.416% |
| ImmuCell Corporation | -2.5 Million USD | 10042.186% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | 290.89% |
| Incyte Corporation | 919.42 Million USD | 72.922% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | 290.933% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 3996.926% |
| Mustang Bio, Inc. | -48.06 Million USD | 617.987% |
| MiMedx Group, Inc. | 40.51 Million USD | -514.458% |
| MEI Pharma, Inc. | 26.38 Million USD | -843.745% |
| MacroGenics, Inc. | 2.01 Million USD | -12243.084% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | -57927.359% |
| Mereo BioPharma Group plc | -26.05 Million USD | 1055.481% |
| Marker Therapeutics, Inc. | -11.79 Million USD | 2211.213% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | 298.379% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 65.054% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | 1247.734% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 1667.758% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | 2441.39% |
| NextCure, Inc. | -59.03 Million USD | 521.687% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | 586.07% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | 2597.592% |
| Onconetix, Inc. | -36.7 Million USD | 778.241% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | -11039.15% |
| Opthea Limited | -200.01 Million USD | 224.468% |
| Ovid Therapeutics Inc. | -58.71 Million USD | 524.027% |
| Psyence Biomedical Ltd. | -2.75 Million USD | 9147.892% |
| PDS Biotechnology Corporation | -40.08 Million USD | 721.081% |
| Precigen, Inc. | -89.22 Million USD | 379.022% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | 1193.753% |
| Prime Medicine, Inc. | -193.75 Million USD | 228.49% |
| PureTech Health plc | -11.62 Million USD | 2241.223% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 205.214% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 94.651% |
| Replimune Group, Inc. | -230.19 Million USD | 208.15% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 261590.631% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | 1566.109% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | 1485.154% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 157.819% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1132.519% |
| Sesen Bio, Inc. | -50.84 Million USD | 589.693% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | 384.763% |
| Solid Biosciences Inc. | -93.43 Million USD | 366.455% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 208.271% |
| SciSparc Ltd. | -5.28 Million USD | 4813.366% |
| Sutro Biopharma, Inc. | -67.91 Million USD | 466.576% |
| TG Therapeutics, Inc. | 26.1 Million USD | -853.87% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | 318.216% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | 3574.669% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 176.311% |
| UroGen Pharma Ltd. | -63.83 Million USD | 490.03% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | 500.277% |
| XOMA Corporation | -39.36 Million USD | 732.488% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 190.366% |
| AbCellera Biologics Inc. | -192.15 Million USD | 229.56% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 538.665% |
| Cassava Sciences, Inc. | -95.68 Million USD | 360.182% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | 660.258% |
| Precision BioSciences, Inc. | -32.04 Million USD | 876.98% |
| Dyadic International, Inc. | -8.22 Million USD | 3125.126% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | 2568.372% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | 85653.265% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 950.913% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | 303.223% |
| IGM Biosciences, Inc. | -253.35 Million USD | 198.264% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | 332.449% |
| Acelyrin, Inc. | -381.52 Million USD | 165.254% |
| Abeona Therapeutics Inc. | -50.57 Million USD | 592.288% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | -144.733% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | 1350.277% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | 1130.208% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 258.377% |
| Senti Biosciences, Inc. | -61.33 Million USD | 505.895% |
| Mesoblast Limited | -61.33 Million USD | 505.928% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 273.854% |
| ChromaDex Corporation | -3.89 Million USD | 6493.426% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | 5295.905% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | 3724.927% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | -100605.456% |
| Seer, Inc. | -97.88 Million USD | 354.339% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | 1148.915% |
| Novavax, Inc. | -487.39 Million USD | 151.08% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | 11166.271% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 244.552% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 577.41% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 210.527% |
| Celcuity Inc. | -58.3 Million USD | 526.96% |
| ContextLogic Inc. | -324 Million USD | 176.84% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 256.53% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | 421.891% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 82.823% |
| Amarin Corporation plc | -50.9 Million USD | 589.101% |
| AnaptysBio, Inc. | -143.16 Million USD | 273.898% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | 979.376% |
| Aptorum Group Limited | -9.59 Million USD | 2693.604% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 205.912% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 241.719% |
| Ardelyx, Inc. | -55.35 Million USD | 549.76% |
| Celularity Inc. | -183.94 Million USD | 235.344% |
| Omeros Corporation | -163.61 Million USD | 252.167% |
| Humacyte, Inc. | -96.45 Million USD | 358.102% |
| Immunocore Holdings plc | -59.64 Million USD | 517.375% |
| IO Biotech, Inc. | -91.22 Million USD | 372.899% |
| GT Biopharma, Inc. | 5.97 Million USD | -4063.907% |
| Cabaletta Bio, Inc. | -73.23 Million USD | 439.951% |
| Summit Therapeutics Inc. | 1 Million USD | -24771.129% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | 905.592% |
| Pulmatrix, Inc. | -12.64 Million USD | 2068.686% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 149.171% |
| Evogene Ltd. | -23.2 Million USD | 1172.918% |
| CorMedix Inc. | -48.88 Million USD | 609.256% |
| BioLineRx Ltd. | -57.06 Million USD | 536.305% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | 867.14% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 909.889% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 175.365% |
| scPharmaceuticals Inc. | -46.06 Million USD | 640.501% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | 329.473% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | -129.829% |
| NLS Pharmaceutics AG | -11.79 Million USD | 2210.608% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | 1132.519% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 267.502% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | 1923.482% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | 1075.587% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | 321.684% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | 402.75% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | 533.91% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | 1497.891% |
| Daré Bioscience, Inc. | -30.7 Million USD | 910.905% |
| bluebird bio, Inc. | -167.16 Million USD | 248.934% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 19.764% |
| DBV Technologies S.A. | -85.98 Million USD | 389.549% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 206.622% |
| Galecto, Inc. | -37.51 Million USD | 763.557% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | 845.702% |
| Spruce Biosciences, Inc. | -47.36 Million USD | 625.609% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 220.449% |
| GlycoMimetics, Inc. | -39.12 Million USD | 736.368% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 209.465% |
| ADMA Biologics, Inc. | 5.12 Million USD | -4762.5% |
| Clene Inc. | -43.24 Million USD | 675.75% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 183.107% |
| Aptose Biosciences Inc. | -52.26 Million USD | 576.314% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | 331.068% |
| Soligenix, Inc. | -7.85 Million USD | 3270.314% |
| Century Therapeutics, Inc. | -121.2 Million USD | 305.399% |
| Kura Oncology, Inc. | -164.95 Million USD | 250.926% |
| Surrozen, Inc. | -41.13 Million USD | 705.286% |
| TScan Therapeutics, Inc. | -80.09 Million USD | 410.819% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | 26094.556% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | 5877.675% |
| Autolus Therapeutics plc | -156.77 Million USD | 258.806% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 394.081% |
| Eterna Therapeutics Inc. | -19.93 Million USD | 1348.921% |
| Caribou Biosciences, Inc. | -112.53 Million USD | 321.231% |
| GRI Bio, Inc. | -10.89 Million USD | 2384.456% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | 5613.191% |
| Janux Therapeutics, Inc. | -71.02 Million USD | 450.529% |
| INmune Bio, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | 339.864% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 752.869% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 1723.909% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | 3126.365% |
| Jaguar Health, Inc. | -33.13 Million USD | 851.441% |
| Entero Therapeutics, Inc. | -15.74 Million USD | 1681.377% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | 537.963% |
| Clearside Biomedical, Inc. | -23.05 Million USD | 1179.712% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 193.595% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 228.37% |
| Verastem, Inc. | -83.16 Million USD | 399.353% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 257.343% |
| Histogen Inc. | -10.5 Million USD | 2470.37% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | 1843.453% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | 467.051% |
| Surrozen, Inc. | -41.13 Million USD | 705.286% |
| Organovo Holdings, Inc. | -14.8 Million USD | 1781.48% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -7762918.397% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | 3085.846% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 249.916% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | 605.416% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | 1753.666% |
| Kronos Bio, Inc. | -121.83 Million USD | 304.35% |
| Turnstone Biologics Corp. | -56.23 Million USD | 542.721% |
| Synaptogenix, Inc. | -8.3 Million USD | 3096.808% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | 1723.052% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | 77657.632% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | 494.88% |
| Exelixis, Inc. | 196.6 Million USD | -26.631% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 276.057% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 150.274% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 483.104% |
| ESSA Pharma Inc. | -26.45 Million USD | 1041.059% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | 6324.084% |
| Avid Bioservices, Inc. | -11.48 Million USD | 2268.452% |
| Insmed Incorporated | -654.73 Million USD | 138.024% |
| MediWound Ltd. | -4.89 Million USD | 5188.085% |
| OmniAb, Inc. | -49.73 Million USD | 600.613% |
| Alector, Inc. | -142.89 Million USD | 274.229% |
| Seres Therapeutics, Inc. | -85.43 Million USD | 391.406% |
| Zai Lab Limited | -366.57 Million USD | 167.916% |
| AlloVir, Inc. | -190.14 Million USD | 230.931% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 185.66% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | 326.847% |
| Aura Biosciences, Inc. | -83.69 Million USD | 397.457% |
| Immunic, Inc. | -99.11 Million USD | 351.191% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | 289.079% |
| Veracyte, Inc. | -49.4 Million USD | 603.876% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | 3624.383% |
| FibroGen, Inc. | -261.4 Million USD | 195.239% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 2334.629% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | -186.781% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | 3655.897% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | 1430.137% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | 1079.309% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | -524.116% |
| Fortrea Holdings Inc. | 167.3 Million USD | -48.811% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | 285.404% |
| XBiotech Inc. | -35.76 Million USD | 796.08% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | 483.104% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 263.599% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | -46962.382% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | 481.548% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | 338.342% |
| Agenus Inc. | -145.92 Million USD | 270.609% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 1069.773% |
| Theravance Biopharma, Inc. | -40.86 Million USD | 709.196% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 148.206% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | 544.405% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | 314.003% |
| Gain Therapeutics, Inc. | -22.16 Million USD | 1222.982% |
| C4 Therapeutics, Inc. | -122.1 Million USD | 303.893% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | 4605.616% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | 1080.466% |
| Lantern Pharma Inc. | -15.78 Million USD | 1677.025% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ainos, Inc. | -8.77 Million USD | 2937.766% |
| Pluri Inc. | -20.22 Million USD | 1330.952% |
| Prothena Corporation plc | -190.1 Million USD | 230.957% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | 294.2% |
| Rallybio Corporation | -72.37 Million USD | 443.996% |
| Kodiak Sciences Inc. | -259.02 Million USD | 196.115% |
| Cue Biopharma, Inc. | -46.05 Million USD | 640.606% |
| MeiraGTx Holdings plc | -57.05 Million USD | 536.374% |
| Annexon, Inc. | -141.57 Million USD | 275.85% |
| Assembly Biosciences, Inc. | -64.19 Million USD | 487.812% |
| Moderna, Inc. | -3.28 Billion USD | 107.583% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | 1385.154% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | 1121.794% |
| Blueprint Medicines Corporation | -474.61 Million USD | 152.455% |
| Immix Biopharma, Inc. | -16.13 Million USD | 1642.919% |
| CalciMedica, Inc. | -34.18 Million USD | 828.187% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | 281.605% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 247.794% |
| Wave Life Sciences Ltd. | -58.79 Million USD | 523.473% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 198.641% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | 855.202% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | 345.971% |
| Nutriband Inc. | -5.12 Million USD | 4960.813% |
| Protara Therapeutics, Inc. | -43.27 Million USD | 675.337% |
| Vor Biopharma Inc. | -114.37 Million USD | 317.678% |
| Roivant Sciences Ltd. | -996.51 Million USD | 124.983% |
| Alkermes plc | 495.04 Million USD | 49.71% |
| ProKidney Corp. | -147.66 Million USD | 268.593% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 485.775% |
| Arcellx, Inc. | -64.14 Million USD | 488.121% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 144.027% |
| Tango Therapeutics, Inc. | -111.75 Million USD | 322.767% |
| Galectin Therapeutics Inc. | -202 Thousand USD | 123347.525% |
| Atai Life Sciences N.V. | -36.31 Million USD | 785.632% |
| Renovaro Biosciences Inc. | -79.51 Million USD | 413.09% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | 406.175% |
| MediciNova, Inc. | -9.87 Million USD | 2619.846% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | 297.68% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 16369.758% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1033.526% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 210.653% |
| Biomea Fusion, Inc. | -124.62 Million USD | 299.775% |
| RenovoRx, Inc. | -11.39 Million USD | 2285.777% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 230.798% |
| Geron Corporation | -174.78 Million USD | 242.44% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 929.176% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | 332.417% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 206.632% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | 1189.302% |
| Royalty Pharma plc | 1.88 Billion USD | 86.808% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 219.787% |
| Imunon, Inc. | -19.87 Million USD | 1352.422% |
| BioAtla, Inc. | -122.24 Million USD | 303.663% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 182.906% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | 700.671% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 249.904% |
| Structure Therapeutics Inc. | -102.45 Million USD | 342.985% |
| 89bio, Inc. | -134.46 Million USD | 285.151% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | 350.831% |
| aTyr Pharma, Inc. | -52.17 Million USD | 577.136% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | 397.035% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 206.137% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | 3195.632% |
| Akari Therapeutics, Plc | -16.8 Million USD | 1581.728% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -131830.092% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 44.914% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 252.303% |
| Liquidia Corporation | -70.05 Million USD | 455.398% |
| Entera Bio Ltd. | -8.8 Million USD | 2927.806% |
| GH Research PLC | -41.15 Million USD | 704.962% |
| Vericel Corporation | 2.86 Million USD | -8592.737% |
| Arbutus Biopharma Corporation | -70.98 Million USD | 450.717% |
| Xencor, Inc. | -125.87 Million USD | 297.785% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | 17551.956% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | 1723.909% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | 1335.067% |
| Vaxcyte, Inc. | -464.88 Million USD | 153.553% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 218.263% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | 2375.27% |
| Lexaria Bioscience Corp. | -6.38 Million USD | 3996.926% |
| Portage Biotech Inc. | -18.19 Million USD | 1467.987% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | 16369.758% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | 338.048% |
| OncoCyte Corporation | -23.12 Million USD | 1176.677% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 2303.115% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 2273.025% |
| Purple Biotech Ltd. | -22.22 Million USD | 1220.18% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | 965.165% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | 959.579% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 247.782% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | 3983.931% |
| Moleculin Biotech, Inc. | -29.5 Million USD | 943.818% |
| United Therapeutics Corporation | 1.38 Billion USD | 82.048% |
| HilleVax, Inc. | -132.46 Million USD | 287.943% |
| Silo Pharma, Inc. | -3.62 Million USD | 6965.563% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | 4170.271% |
| Pharming Group N.V. | 9.87 Million USD | -2420.603% |
| Tharimmune, Inc. | -9.3 Million USD | 2776.244% |
| Genprex, Inc. | -31.06 Million USD | 901.531% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 396.434% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 232.76% |
| Pyxis Oncology, Inc. | -78.49 Million USD | 417.175% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | 32686.387% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | -164879.06% |
| OKYO Pharma Limited | -15.74 Thousand USD | 1581213.016% |
| Savara Inc. | -59.13 Million USD | 521.017% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | 1334.982% |
| Curis, Inc. | -45.13 Million USD | 651.541% |
| Carmell Therapeutics Corporation | -15.19 Million USD | 1738.849% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | 1031.249% |
| BeiGene, Ltd. | -1.12 Billion USD | 122.137% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | 375.581% |
| Erasca, Inc. | -121.31 Million USD | 305.226% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 5633.974% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | 5633.974% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 684.29% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | 4507.932% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | 515.959% |
| Celldex Therapeutics, Inc. | -139.03 Million USD | 279.064% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 220.937% |
| Adicet Bio, Inc. | -136.53 Million USD | 282.342% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | 370.377% |
| Aditxt, Inc. | -25.45 Million USD | 1077.926% |
| Adagene Inc. | -14.95 Million USD | 1765.197% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 3505.7% |
| Quantum-Si incorporated | -91.8 Million USD | 371.186% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | -96.876% |
| Compugen Ltd. | -12.51 Million USD | 2089.134% |
| Generation Bio Co. | -133.3 Million USD | 286.767% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 399.843% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | 389.411% |
| Invivyd, Inc. | -196.61 Million USD | 226.623% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 166.54% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | 2784.263% |
| Spero Therapeutics, Inc. | 27.15 Million USD | -816.845% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 2520.613% |
| 2seventy bio, Inc. | -206.41 Million USD | 220.61% |
| Instil Bio, Inc. | -146.12 Million USD | 270.378% |
| Capricor Therapeutics, Inc. | -23 Million USD | 1182.012% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | 5929.977% |
| GeoVax Labs, Inc. | -26.66 Million USD | 1033.526% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | 777.823% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | -4970.205% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 257.168% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 136.381% |
| Evaxion Biotech A/S | -21.4 Million USD | 1263.201% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | 474.855% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 214.375% |
| Tyra Biosciences, Inc. | -79.59 Million USD | 412.795% |
| Cingulate Inc. | -22.95 Million USD | 1184.697% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | 3436.818% |
| Unity Biotechnology, Inc. | -37.28 Million USD | 767.757% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | 526.506% |
| Clearmind Medicine Inc. | -8.71 Million USD | 2958.106% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | 434.885% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 10297.369% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 346.918% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 165.521% |
| ImmunityBio, Inc. | -436.18 Million USD | 157.077% |
| Korro Bio, Inc. | -80.9 Million USD | 407.723% |
| Kineta, Inc. | -15.71 Million USD | 1684.32% |
| BioVie Inc. | -31.95 Million USD | 879.212% |
| Codexis, Inc. | -49.28 Million USD | 605.164% |
| Celularity Inc. | -183.94 Million USD | 235.344% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | 1694.569% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 212.392% |
| Virax Biolabs Group Limited | -6.6 Million USD | 3866.902% |
| Cibus, Inc. | -314.58 Million USD | 179.139% |
| IN8bio, Inc. | -28.5 Million USD | 973.421% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | 321.103% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | 990.574% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 208.239% |
| Eyenovia, Inc. | -24.1 Million USD | 1132.77% |
| Puma Biotechnology, Inc. | 44.78 Million USD | -455.913% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 76939.506% |
| Elevation Oncology, Inc. | -41.46 Million USD | 700.381% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | 437.326% |
| Cardiff Oncology, Inc. | -45.01 Million USD | 653.072% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | 301.626% |
| Regulus Therapeutics Inc. | -30.88 Million USD | 906.165% |
| Moolec Science SA | -52.07 Million USD | 578.075% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | 582.425% |
| LAVA Therapeutics N.V. | -40.41 Million USD | 715.978% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | 308.173% |
| Compass Therapeutics, Inc. | -48.47 Million USD | 613.606% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 2770.026% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | 1300.342% |
| Humacyte, Inc. | -96.45 Million USD | 358.102% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | 415.639% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | -6044.126% |
| Genelux Corporation | -24.16 Million USD | 1130.25% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | 836.568% |
| Notable Labs, Ltd. | -14.4 Million USD | 1828.889% |
| Immunovant, Inc. | -269.97 Million USD | 192.215% |
| Quantum-Si incorporated | -91.8 Million USD | 371.186% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | 1389.414% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 344.05% |
| Acasti Pharma Inc. | -11.3 Million USD | 2302.991% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | 1218.758% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | 772.32% |
| PepGen Inc. | -83.58 Million USD | 397.863% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 1187.304% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | 5317.388% |
| Immuneering Corporation | -58.06 Million USD | 528.792% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | -7762918.397% |
| Belite Bio, Inc | -31.52 Million USD | 889.622% |
| XOMA Corporation | -39.36 Million USD | 732.488% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | 469.119% |
| Bionomics Limited | -9.83 Million USD | 2630.854% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 819.413% |
| uniQure N.V. | -253.1 Million USD | 198.364% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 3505.7% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 292.241% |
| Forte Biosciences, Inc. | -32.47 Million USD | 866.573% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | 3192.489% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | 982.242% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | 76939.506% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | 2334.629% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | 1665.688% |
| Altimmune, Inc. | -87.93 Million USD | 383.118% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | 303.658% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | 819.413% |
| Peak Bio, Inc. | -1356.23 USD | 18356868.395% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | 612.284% |
| Benitec Biopharma Inc. | -22.49 Million USD | 1206.981% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 202.747% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | 972.228% |
| Zura Bio Limited | -60.56 Million USD | 511.076% |
| PolyPid Ltd. | -20.26 Million USD | 1328.643% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | 972.228% |
| argenx SE | -216.02 Million USD | 215.247% |
| Immunome, Inc. | -28.27 Million USD | 980.62% |
| Verona Pharma plc | -52.46 Million USD | 574.502% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | 362.694% |
| Shattuck Labs, Inc. | -87.61 Million USD | 384.152% |
| CervoMed Inc. | -2.17 Million USD | 11562.912% |
| Plus Therapeutics, Inc. | -12.69 Million USD | 2061.396% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 616.793% |
| Moolec Science SA | -52.07 Million USD | 578.075% |
| Enveric Biosciences, Inc. | -17.13 Million USD | 1552.51% |
| Design Therapeutics, Inc. | -66.32 Million USD | 475.364% |
| Leap Therapeutics, Inc. | -80.98 Million USD | 407.407% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | 759.497% |
| Achilles Therapeutics plc | -70.44 Million USD | 453.426% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | 10297.369% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | 549.127% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | 592.502% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | 481.39% |
| MoonLake Immunotherapeutics | -54.1 Million USD | 560.1% |
| Tourmaline Bio, Inc. | -45.37 Million USD | 648.66% |
| Beam Therapeutics Inc. | -156.47 Million USD | 259.107% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | 282.402% |
| AEON Biopharma, Inc. | -48.36 Million USD | 614.795% |
| Aadi Bioscience, Inc. | -65.36 Million USD | 480.877% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | 403.862% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | 2115.867% |
| NeurAxis, Inc. | -6.66 Million USD | 3835.617% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 158.246% |
| Lumos Pharma, Inc. | -36.57 Million USD | 780.777% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | -4170.878% |
| Palisade Bio, Inc. | -12.28 Million USD | 2127.196% |
| Nutriband Inc. | -5.12 Million USD | 4960.813% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | 336.661% |
| Neurogene Inc. | -52.28 Million USD | 576.15% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | 3065.222% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | 367.647% |
| Athira Pharma, Inc. | -116.7 Million USD | 313.328% |
| HCW Biologics Inc. | -23.57 Million USD | 1155.987% |
| XOMA Corporation | -39.36 Million USD | 732.488% |
| Nektar Therapeutics | -243.1 Million USD | 202.408% |
| Arvinas, Inc. | -394.8 Million USD | 163.06% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | -131830.092% |
| Merus N.V. | -149.2 Million USD | 266.855% |
| Omega Therapeutics, Inc. | -93.49 Million USD | 366.296% |
| Quince Therapeutics, Inc. | -31.26 Million USD | 896.417% |
| Rezolute, Inc. | -68.42 Million USD | 463.854% |
| Clene Inc. | -43.24 Million USD | 675.75% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 1714.297% |
| BeyondSpring Inc. | -21.54 Million USD | 1255.803% |
| Synlogic, Inc. | -55.16 Million USD | 551.333% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | 2160.415% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | 2439.41% |
| Peak Bio, Inc. | -1356.23 USD | 18356868.395% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | 866.857% |
| Krystal Biotech, Inc. | 17.9 Million USD | -1290.527% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | 310.229% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 172.935% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | 5504.617% |
| MannKind Corporation | 15.12 Million USD | -1545.581% |
| Ikena Oncology, Inc. | -74.39 Million USD | 434.637% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | 2076.971% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | -1124.775% |
| Gossamer Bio, Inc. | -172.15 Million USD | 244.616% |
| CohBar, Inc. | -12.06 Million USD | 2163.36% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | 1075.969% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | 929.176% |
| Legend Biotech Corporation | -477.87 Million USD | 152.098% |
| Mural Oncology plc | -192.72 Million USD | 229.182% |
| Disc Medicine, Inc. | -91.02 Million USD | 373.507% |
| Champions Oncology, Inc. | -5.05 Million USD | 5025.999% |
| REGENXBIO Inc. | -239.46 Million USD | 203.966% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 2422.781% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 546.517% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | 742.175% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | 320.697% |
| Vaxart, Inc. | -74.72 Million USD | 433.177% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | 807.106% |
| Cellectis S.A. | -98.09 Million USD | 353.795% |
| Longeveron Inc. | -20.06 Million USD | 1341.077% |
| Repare Therapeutics Inc. | -114.27 Million USD | 317.864% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 156.685% |
| Inozyme Pharma, Inc. | -74.81 Million USD | 432.781% |
| Revolution Medicines, Inc. | -430.58 Million USD | 157.819% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | 4058.658% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | 908.6% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 433.771% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | -4977.708% |
| Anixa Biosciences, Inc. | -10.96 Million USD | 2370.497% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 94.594% |
| Denali Therapeutics Inc. | -179.97 Million USD | 238.332% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | 261590.631% |
| Veru Inc. | -89.97 Million USD | 376.697% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | 1026.259% |
| Cingulate Inc. | -22.95 Million USD | 1184.697% |
| Passage Bio, Inc. | -98.34 Million USD | 353.16% |
| Context Therapeutics Inc. | -25.06 Million USD | 1093.433% |
| Exicure, Inc. | -15.53 Million USD | 1702.162% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 220.817% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | 773.302% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | 4275.363% |
| Nuvalent, Inc. | -149.49 Million USD | 266.537% |
| ABVC BioPharma, Inc. | -8.13 Million USD | 3161.329% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | 389.846% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | 924.972% |
| OmniAb, Inc. | -49.73 Million USD | 600.613% |
| Anew Medical, Inc. | -1.3 Million USD | 19238.403% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | 2113.588% |
| Lipocine Inc. | -16.32 Million USD | 1625.241% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | 473.421% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | 435.06% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | 752.869% |
| G1 Therapeutics, Inc. | -39.01 Million USD | 738.13% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | 1222.301% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 145.675% |
| Ocugen, Inc. | -64.82 Million USD | 484.038% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | 368.942% |
| Q32 Bio Inc. | -86.5 Million USD | 387.808% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | 1570.786% |
| Alumis Inc. Common Stock | -156.89 Million USD | 258.684% |
| Equillium, Inc. | -12.13 Million USD | 2151.079% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | 525.776% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 3250.057% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 1419.974% |
| Dominari Holdings Inc. | -22.44 Million USD | 1209.447% |
| Edesa Biotech, Inc. | -8.19 Million USD | 3139.752% |
| vTv Therapeutics Inc. | -25.41 Million USD | 1079.695% |
| Bio-Techne Corporation | 326.66 Million USD | 23.787% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 164.688% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | -15.052% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | 289.889% |
| Candel Therapeutics, Inc. | -37.43 Million USD | 765.117% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 264.764% |
| Nkarta, Inc. | -120.48 Million USD | 306.638% |
| BioCardia, Inc. | -11.56 Million USD | 2253.633% |
| Iterum Therapeutics plc | -34.58 Million USD | 819.954% |